Oral Cancer News – Page 271 – The Oral Cancer Foundation News Archive

Swedish snuff more addicting?

Source: www.upi.com Author: staff A Swedish tobacco company adds a substance to snuff products to heighten dependency, an investigative report concluded. The usual level for snuff or 'snus' is eight milligrams per gram but double that amount was found in one product produced by Swedish Match, the news program Kalla Fakta reported. The report alleges that Swedish Match added a substance known as E500 which raises "free" nicotine to increase craving. The tobacco company denies any wrongdoing. "There is no secret substance in snus," spokesman Henrik Brehmer said regarding the use of E500. "We use it to stabilize the pH value in snus and have done so for 200 years." Brehmer rejected an assertion by Harvard School of Public Health Professor Greg Connolly Swedish Match is deliberately using the substance to addict consumers. "In a study in 2008 he concluded that we are manipulating the pH value, something that we consider hugely speculative," Brehmer said.

Oral Cancer Foundation News Team - A2009-10-26T18:47:47-07:00October, 2009|Oral Cancer News|

Completion of Cel-Sci’s new facility signals that long awaited phase III trial is imminent

Source: www.reuters.com Author: press release BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial. Multikine is the company's flagship immunotherapeutic head and neck cancer treatment and is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Because it required a very specific cold-fill process for manufacturing, the Phase III trials have been on hold as Cel Sci dedicated the majority of their time and resources to build the new best-in-class production facility. Additionally, once the facility is validated, Cel Sci will become the only entity offering the 4°C cold fill on a contract basis, meaning the potential to bring in significant revenue as an added bonus does exist.

Oral Cancer Foundation News Team - A2009-10-26T14:46:03-07:00October, 2009|Oral Cancer News|

Calif. doctor, minister who promised herbal cancer cure to faithful arrested on fraud charges

Source: HealthNews Author: Greg Risling Calif. doc who hailed herbal cancer cure arrested LOS ANGELES — Dr. Christine Daniel promised to her patients what many considered the improbable — the chance to cure cancer through an herbal treatment. Using her influence as an ordained Pentecostal minister, Daniel tapped into the vessel of faith to entice people from across the nation to try her regimen. She even appeared on cable’s Trinity Broadcasting Network in December 2002 touting her cancer cure and its 60 percent success rate, according to federal investigators. Daniel, 55, of Los Angeles was arrested and charged Thursday with two counts each of wire and mail fraud and faces up to 80 years in prison if convicted. She is scheduled to appear in federal court Friday. A phone message left for Daniel’s attorney, Manuel Miller, was not immediately returned. Daniel was interviewed by investigators in August 2004, and she denied ever practicing alternative medicine for cancer, court documents show. She also attested that she never talked about a 60 percent cancer cure rate on television. In court documents, authorities contend Daniel took advantage of terminally ill cancer patients in their darkest hours, some of whom desperately sought alternative measures after enduring draining rounds of chemotherapy and radiation. In all, federal prosecutors said Daniel siphoned about $1.1 million from 55 families between 2001 and 2004. Six patients ranging in age from 4 to 69 died within seven months after seeing Daniel. One of those was Margaret Antwi, who traveled from [...]

Charlotte Parker2009-10-26T11:38:35-07:00October, 2009|Oral Cancer News|

HPV vaccine fails to get nod for routine use in boys

Source: Medscape.com Author: Robert Lowes October 21, 2009 — Despite hearing impassioned pleas to protect both men and women from cancer, a federal advisory panel today declined to recommend that a human papillomavirus (HPV) vaccine be routinely administered to boys to prevent genital warts. Instead, the Advisory Committee on Immunization Practices (ACIP) issued a "permissive" recommendation stating that physicians have the option of vaccinating boys with the HPV vaccine Gardasil(Merck) for genital-wart protection. ACIP noted that boys should receive the vaccine "before exposure to HPV through sexual contact." In 2006, the US Food and Drug Administration (FDA) approved Gardasil for use in girls and young women to prevent cervical and other cancers as well as precancers caused by HPV types 16 and 18. Last week, the FDA also approved Gardasil for use in males aged 9 through 26 to prevent genital warts. In making its recommendation today, ACIP appeared to be swayed in part by published research questioning the cost-effectiveness of routine vaccination of boys with Gardasil. The committee's decision has far-reaching economic effects because third-party payers typically pay for vaccinations that are recommended for routine use, but not those coming with a permissive recommendation. More at Stake Than Genital Wart Prevention Proponents of routine vaccination of boys with Gardasil told the committee Wednesday during the public comment period that more was at stake than merely preventing genital warts. They underlined the need to also prevent oral, throat, penile, and anal cancers caused by HPV. David Hastings, a spokesperson for the [...]

Charlotte Parker2009-10-26T09:22:06-07:00October, 2009|OCF In The News, Oral Cancer News|

Magic gel help Julie Andrews sing again

Source: www.dailymail.co.uk Author: Fiona Macrae The stage may soon be alive with the sound of her famous voice once more. Dame Julie Andrews could have her vocal cords, which were ruined during a throat operation, restored by one of the world's leading scientists. The Sound Of Music Star has been unable to sing since disastrous surgery to remove non-cancerous throat nodules in 1997. But a breakthrough by chemical engineer Robert Langer of the Massachusetts Institute of Technology in the US, could give her back the clear soprano voice that won her many a lead role. He has created a rubbery gel that restores the elasticity to damaged and scarred vocal cords. Trials on rats and ferrets were successful, and the first human patients, perhaps including Dame Julie, could be treated in as little as a year. Professor Langer, who is collaborating with the singer's voice specialist Dr Steven Zeitels, said: 'So far the animal trials have been promising. It appears safe in animals. 'We hope we can start a clinical trial on this gel in a year or two. 'I don't want to promise we'll do it on Julie Andrews but she has been a big proponent of it.' Dame Julie, who received a £600,000 pay-out after the botched operation, is a regular visitor to the Professor's Boston laboratory. The scientist said: 'She can't really hold a note. She had a five octave voice at one point.' The treatment could help anyone whose voice may have been strained by frequent [...]

Oral Cancer Foundation News Team - A2009-10-23T07:40:12-07:00October, 2009|Oral Cancer News|

Research uproar at a cancer clinic

Source: Author: Duff Wilson Two years after becoming vice president for research at the biggest hospital in this university town, Suzanne Stratton said she had finally seen enough She had clashed repeatedly with a doctor who oversaw the local patients enrolled in more than 130 federally sponsored cancer studies — work that the hospital promoted in local television advertisements but that Dr. Stratton, who has a Ph.D. in molecular biology, said was often putting patients and science at risk. In a meeting with Carle Foundation Hospital administrators late last year, Dr. Stratton demanded that they take action. She cited an outside audit that had found “major deficiencies” in 12 of 29 experiments being overseen by that doctor, potentially endangering patients or skewing the studies’ results. Dr. Stratton says her bosses responding by firing her, ushering her out of the hospital later that same day. But federal officials, alerted by Dr. Stratton, have corroborated many of the shortcomings she found. They are continuing to investigate — an inquiry with implications for the nation’s cancer research effort that go far beyond the Carle Cancer Center. In the last quarter century, among the hundreds of thousands of people around the nation who have enrolled in federally financed trials of cancer drugs and treatments, more than one-third have come through the doors of local medical centers like Carle. Together, these nearly 400 federally designated community research sites and the network of 3,400 participating physicians amass more evidence for cancer science than at any of [...]

Oral Cancer Foundation News Team - A2009-10-23T07:16:57-07:00October, 2009|Oral Cancer News|

US advisers decline to push Gardasil for boys

Source: Reuters.com Author: Maggie Fox * Committee advises that doctors free to use vaccine * Says needs more evidence of cost benefit * Did not consider value in preventing cancer (Updates throughout, adds quotes, share price) WASHINGTON, Oct 21 (Reuters) - U.S. vaccine advisers declined to press for the use of Merck & Co's (MRK.N) Gardasil in boys and men, opting instead on Wednesday to simply advise doctors they are free to use it. Despite some impassioned pleas from patients and doctors alike, the Advisory Committee on Immunization Practices voted almost unanimously for "permissive" use of the vaccine for boys. It protects against the human papillomavirus, or HPV, which causes a variety of cancers and genital warts. But the committee did recommend including Gardasil for eligible boys aged 9 to 18 in the Vaccines For Children program, a government-funded system that provides vaccines to children eligible for the state-federal Medicaid health insurance plan and other uninsured children. Merck's shares were down 1.7 percent at $33.16 in afternoon trading on the New York Stock Exchange. The U.S. Centers for Disease Control and Prevention currently recommends Gardasil for girls 11 and 12 years old and women 13 to 26 who have not been vaccinated. Earlier this month, the U.S. Food and Drug Administration approved Gardasil for preventing genital warts in boys and men ages 9 through 26. The main reason the vaccine was approved was to prevent cervical cancer, which kills 4,000 women a year in the United States alone. But various [...]

Charlotte Parker2009-10-21T14:45:00-07:00October, 2009|OCF In The News, Oral Cancer News|

Head and neck cancer surgery patients at major risk of developing myocardial ischaemia

Source: www.docguide.com/news Author: Lexa W. Lee Of patients with head and neck cancer who have undergone surgery, 15% will develop postoperative myocardial ischemia, according to a study presented here October 19 at the 2009 Annual Meeting of the American Society of Anesthesologists (ASA). In addition, ischaemia is a strong predictor of 60-day mortality following surgery, according to presenter Lesley Rao, MD, Washington University, St. Louis, Missouri. For the study, researchers performed a retrospective cohort study of 378 patients who underwent major head and neck cancer surgery. Potential risk factors for postoperative myocardial ischemia, such as heart disease and smoking history, were recorded. Troponin levels were serially measured up to the fifth day after surgery. Peak postoperative troponin I (TnI) concentration was the main outcome variable; a level over 0.1 ng/mL was considered abnormally high. Of the 378 patients, 57 patients (15%) developed an elevated TnI; 90% of which occurred within 24 hours after surgery. A history of renal insufficiency, coronary artery disease, peripheral vascular disease, hypertension, and combined chemotherapy and radiation were associated with elevated postoperative TnI. This group had a significantly longer length of stay in the hospital compared with those with lower TnI levels (8.5 vs 10.1 days; P = .014), ICU stay (3 vs 4.5 days; P = .001), and an 8-fold higher risk of death at 60 days following surgery (odds ratio [OR] = 7.62; 95% confidence interval [CI], 1.98-29.31). At 1 year, patients with an abnormally high postoperative TnI were twice as likely to die [...]

Oral Cancer Foundation News Team - A2009-10-21T04:50:16-07:00October, 2009|Oral Cancer News|

FDA approves two HPV vaccines: Cervarix for girls, Gardasil for boys

Sources: www.cancer.gov/ncicancerbulletin Author: news bulletin The FDA has approved a second vaccine to prevent cervical cancer and cervical precancers, the vaccine’s manufacturer, GlaxoSmithKline, announced last week. The approval is based on data from a large clinical trial showing that the vaccine, Cervarix, prevented precancerous lesions in 93 percent of those who received the full vaccine sequence of three injections over 6 months. Cervarix is a bivalent vaccine, meaning it is specifically designed to protect against two human papillomavirus (HPV) types, HPV 16 and 18, which together are responsible for three-quarters of cervical cancers in North America. Clinical trial data also indicate that Cervarix offers more modest protection against precancerous lesions associated with HPV 31, GSK explained in a statement, as well as other tumor-causing (or oncogenic) HPV types. The company expects the vaccine to be available in the United States by the end of the year. The FDA last week also approved the HPV vaccine Gardasil for the prevention of genital warts in boys. Gardasil is already approved and is being actively used in girls and young women for the prevention of cervical cancer. Gardasil is a quadrivalent vaccine that is designed to specifically protect against infections with four HPV types: 16, 18, 6, and 11. HPV types 6 and 11, which are not considered to be oncogenic, cause genital warts. The agency’s approval of Gardasil for boys aged 9 to 26 is based on data from a randomized clinical trial of more than 4,000 males aged 16 to 26, [...]

Oral Cancer Foundation News Team - A2009-10-21T04:44:55-07:00October, 2009|Oral Cancer News|

Doctor’s word–tips to escape the smoking trap

Source: news.ncmonline.com Author: Erin Marcus, M.D. Editor's Note: In the debut of A Doctor's Word, Dr. Erin Marcus wrote about an African-American man's effort to quit smoking cigarettes. This week, she offers practical advice for all who would like to kick the habit. Dr. Marcus is associate professor of clinical medicine at the University of Miami Miller School of Medicine. In my first column, I shared the story of Lawrence Jones, a 55-year-old man who smoked for 35 years until July, when he decided to quit. In his words, he was “sick and tired of being sick and tired.” Giving up the addictive habit of tobacco is extremely difficult, and Jones’ success depended on the help of a counselor, smoking cessation classes, nicotine replacement patches, and the support of a friend. Here are some things that helped Jones, as well as tips I’ve garnered over the years as a primary care physician. To succeed at quitting, you first have to decide that this is something you really want to do. Medicine and classes won’t work unless you have made a commitment. In Jones’ case, a graphic video that his counselor played at his first stop smoking class made him resolve to quit. It showed pictures of smokers that he could not forget: a man missing an eye and part of his nose from mouth cancer, and people breathing through tracheotomies – holes that doctors surgically cut in their throats when cancer prevented them from breathing. “You have to be willing [...]

Oral Cancer Foundation News Team - A2009-10-20T13:11:52-07:00October, 2009|Oral Cancer News|